Stevens-Johnson induced by imiquimod 5% cream: a case report.

Imiquimod 5% cream is an approved treatment for actinic keratoses, superficial basal cell carcinomas, and anogenital warts. Severe systemic side effects associated with imiquimod 5% cream are rare, although a few cases of erythema multiforme and Stevens-Johnson syndrome have been described. We present a case of Stevens-Johnson syndrome associated with topical treatment with imiquimod of two superficial basal cell carcinomas.

Spatiotemporal Mapping of the Evolution of Silver Nanoparticles in Living Cells.

Bioaccumulated silver nanoparticles (AgNPs) can undergo transformation and release toxic Ag, which can be further reduced and form secondary AgNPs (AgNPs). However, the intricate interconversions among AgNPs, Ag, and AgNPs remain speculative. Herein, we developed a bioimaging method by coupling the aggregation-induced emission method with the label-free confocal scattering and hyperspectral imaging techniques to quantitatively visualize the biodistribution and biotransformation of AgNPs, AgNPs, and Ag in living cells.

Impact of Psoriasis on Pregnancy Desire and Possible Consequences on Fertility.

Introduction: Approximately half of patients affected by psoriasis are women, and the management of female patients of childbearing age is an under-investigated topic. Some studies have shown a significant decrease in births in psoriatic patients due to intimacy and pregnancy avoidance and to potential birth complications.

Objectives: We sought to evaluate data on reproductive health in a cohort of female patients, to compare them with similar data in the general population and to assess the impact of psoriasis, especially genital psoriasis, on pregnancy desire and the prevalence of psoriasis in the children of patients with psoriasis.

Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease.

Secondary acute myeloid leukemia (s-AML) is associated with inferior outcomes with conventional chemotherapy, and fludarabine combinations (FLAG-Ida) have been tested to improve results. More recently, CPX-351 resulted superior to conventional 3 + 7 in s-AML patients. In the UK NCRI AML19 trial, AML patients were randomized to receive either FLAG-Ida or CPX-351.